BioCentury
ARTICLE | Finance

Hopp stays the course

CureVac reflects dievini Hopp high risk-high reward investment strategy

September 24, 2012 7:00 AM UTC

Despite experiencing mixed results over the past year, the Hopp family remains committed to placing big bets on innovative biotechnologies. In the latest example, the firm provided CureVac GmbH with €80 million to generate Phase IIb survival data for an mRNA cancer vaccine, which it hopes will attract a partner for Phase III testing.

SAP AG co-founder Dietmar Hopp was a business angel to biotech companies for four years before pairing up with advisory firm dievini GmbH in 2005 to form dievini Hopp BioTech Holding GmbH & Co. KG as the Hopp family investment vehicle...